title: Pazopanib and anti-VEGF therapy.
abstract: Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant diseases are presented. Based on available evidence, pazopanib is an effective VEGFR inhibitor with demonstrable clinical activity in metastatic RCC and promising activity in other diseases. Like most kinase inhibitors, its activity is not restricted to VEGF receptors, which is reflected in its side-effect profile.
authors.affiliation: Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA.
authors.forename: Harry A
authors.initials: HA
authors.lastname: Drabkin
keywords: VEGFR; pazopanib; renal cell carcinoma